Your browser doesn't support javascript.
loading
Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma.
Wang, Rong; Li, Liang; Duan, Aijun; Li, Yi; Liu, Xiujun; Miao, Qingfang; Gong, Jianhua; Zhen, Yongsu.
Afiliação
  • Wang R; NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China; Department of Blood Transfusion, The Affiliated Hospital of Qingdao University, Qingdao, Shandong,
  • Li L; NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Duan A; NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Li Y; NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Liu X; NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
  • Miao Q; NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: miaoqf@sina.com.
  • Gong J; NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Electronic address: ann_gong@hotmail.com.
  • Zhen Y; NHC Key Laboratory of Biotechnology of Antibiotics, Department of Oncology, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Cancer Lett ; 448: 84-93, 2019 04 28.
Article em En | MEDLINE | ID: mdl-30742941
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Anaplásico de Células Grandes / Antígeno Ki-1 / Inibidores de Proteínas Quinases / Crizotinibe / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2019 Tipo de documento: Article País de publicação: Irlanda
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Linfoma Anaplásico de Células Grandes / Antígeno Ki-1 / Inibidores de Proteínas Quinases / Crizotinibe / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Cancer Lett Ano de publicação: 2019 Tipo de documento: Article País de publicação: Irlanda